ARID1A has also been associated with impaired DNA damage repair, and, in colorectal cancer, ARID1A was enriched in patients who developed resistance to an anti-EGFR monoclonal antibody, suggesting it may play a role in resistance in this setting [8,9]. This evidence concerns the gene ARID1A and colorectal cancer.